Mϕs promote tissue injury or repair depending on their activation status and the local cytokine milieu. It remains unclear whether the immunosuppressive effects of transforming growth factor β (TGF-β) serve a nonredundant role in Mϕ function in vivo. We generated Mϕ-specific transgenic mice that express a truncated TGF-β receptor II under control of the CD68 promoter (CD68TGF-βDNRII) and subjected these mice to the dextran sodium sulfate (DSS) model of colitis. CD68TGF-βDNRII mice have an impaired ability to resolve colitic inflammation as demonstrated by increased lethality, granulocytic inflammation, and delayed goblet cell regeneration compared with transgene negative littermates. CD68TGF-βDNRII mice produce significantly less IL-10, but have increased levels of IgE and numbers of IL-33+ Mϕs than controls. These data are consistent with associations between ulcerative colitis and increased IL-33 production in humans and suggest that TGF-β may promote the suppression of intestinal inflammation, at least in part, through direct effects on Mϕ function.
Damage within the gastrointestinal mucosa can be induced by a wide variety of physical, chemical, and/or infectious stimuli 1. Inflammatory bowel disease (IBD) such as Crohn's colitis and ulcerative colitis (UC) generally result in epithelial cell death, loss of crypt architecture, submucosal edema, and mucosal ulceration 2. The relapsing/remitting episodes of IBD 3 are associated with marked variations in pro-inflammatory cytokine production 4, 5; therefore, mouse models of IBD have been used to investigate the regulatory mechanisms that reduce inflammation and restore intestinal homeostasis 6.
Dextran sodium sulfate (DSS)-induced colitis is a transient, myeloid-dependent gut injury model driven by epithelial cell damage 7. The severity of DSS colitis may be controlled by anti-inflammatory cytokines such as IL-10 and transforming growth factor β (TGF-β) 8, but it is unclear whether these cytokines can directly modulate Mϕ function(s) in ways that promote the resolution of inflammation following the termination of DSS-induced injury 9–14. Furthermore, it is unknown whether IL-10 and TGF-β have redundant effects on Mϕ function 15, 16.
TGF-β has multiple biological effects on hematopoietic and nonhematopoietic cells 17. Binding of TGF-β to TGF-βRII phosphorylates SMAD transcription factors that are primarily immunosuppressive in function 17. Genetic mutations in TGF-βRII are linked to UC and colitis-associated cancer in humans 18–20 and mice that lack TGF-β responsiveness in epithelial cells or T lymphocytes develop severe intestinal inflammation 21, 22. Whether TGF-β suppresses colitic inflammation through direct effects on Mϕs is unknown.
Herein, we employed the DSS colitis model to demonstrate that lack of TGF-β responsive Mϕs impairs the normal resolution of colitic inflammation. CD68TGF-βDNRII mice produce high levels of IL-33, an IL-1 family cytokine that is overexpressed in the colonic mucosa of UC patients 23–25. CD68TGF-βDNRII mice also produced significantly less IL-10 than littermate controls during colitis resolution. Taken together, these data show an important role for TGF-β in the specific regulation of intestinal Mϕ function in vivo.
Generation of Mϕ-specific TGF-β dominant negative receptor mice
A transgenic construct was generated to contain the human CD68 promoter (CD68-IVS1) 26, 27 followed by a human TGF-β receptor II lacking the cytoplasmic domain 28 (Fig. 1A). This truncated receptor binds its extra-cellular ligand (TGF-β1, TGF-β2, and TGF-β3) but does not signal; therefore, it antagonizes TGF-β function in the cell by acting as a competitive inhibitor. This approach has been employed in a variety of tissue-specific promoter systems 21, 28–32. Pronuclear injection of C57BL/6 oocytes allowed generation of a founder (designated CD68TGF-βDNRII) possessing a single integration of approximately 15–20 copies (Fig. 1B). Thioglycollate-elicited peritoneal exudates cells (PECs) were evaluated by flow cytometry to determine the specificity of transgene expression. Compared with nontransgenic littermates, CD68TGF-βDNRII mice demonstrate TGF-βRII protein expression on CD11b+ myeloid cells (0.12 versus 5.3%), F4/80+ Mϕs (0.27 versus 7.9%), but not on CD11c+ dendritic cells (0.15 versus 0.32%), respectively (Fig. 1C). Transgene expression was not detected on granulocytes (GR-1+), B lymphocytes (B220+), or T lymphocytes (CD3+) from spleen (data not shown).
To determine whether Mϕs from CD68TGF-βDNRII mice had functionally impaired TGF-β responsiveness, the adherent fraction of thioglycollate-elicited peritoneal cells (PECs) (>90% Mϕs) was tested for IL-10 versus TGF-β-mediated suppression of endotoxin (LPS)-induced cytokine production. As expected, LPS induced a 1000-fold increase of IL-12/23p40 production within 24 h that was significantly suppressed by pretreatment with IL-10 in both WT and CD68TGF-βDNRII groups (Fig. 1D). On the contrary, LPS-induced 12/23p40 production was moderately suppressed in TGF-β-pretreated WT PECs, which was not observed following the treatment of CD68TGF-βDNRII PECs (Fig. 1D). IL-10 is induced in Mϕ following exposure to LPS 33 or TGF-β 34. Figure 1E shows equivalent LPS-induced IL-10 production, but significantly impaired TGF-β-induced IL-10 production in CD68TGF-βDNRII PECs compared with WT. To determine whether overexpression of the mutant human TGF-βRII affected the endogenous murine TGF-β RII, lamina propria mononuclear cells from naïve WT and CD68TGF-βDNRII mice were evaluated by flow cytometry. Human TGF-βRII was detected on both CD11c+ F4/80+ and F4/80+ populations within the colon, but there were no differences between strains in the mean fluorescence intensity (MFI) of mouse TGF-βRII expression on any of the gated cell populations (Fig. 2). Transgene expression was specific, because CD3+CD4− and CD3+CD4+ lymphocytes showed no differences in staining for human or mouse TGF-βRII although lymphocytes expressed comparatively higher levels of TGF-βRII than the myeloid cell populations (Supporting Information Fig. 1). Thus, CD68TGF-βDNRII mice have a specific expression of a truncated human TGFβRII and impairment of TGF-β-dependent functions in Mϕs.
Defective resolution of DSS-induced colitis in CD68TGF-βDNRII mice
Administration of 2.5% DSS ad libitum for 6 days to WT C57BL/6 mice causes a transient colitis that rapidly resolves following the return of mice to normal untreated drinking water 3, 7. CD68TGF-βDNRII mice administered 2% DSS lost weight at a slightly faster rate than WT littermates during the initial stages of colitis induction (Fig. 3A), but demonstrated impaired weight gain following the termination of DSS administration (Fig. 3A). Although there were no differences in mortality at this dose (Fig. 3B), there was increased severity of the clinical disease indicators (hunched posture, fecal blood, and diarrhea) in CD68TGF-βDNRII mice compared with controls (Fig. 3C). On the contrary, CD68TGF-βDNRII mice administered 2.5% DSS rapidly lost >25% of their initial body weight (Fig. 3D) and 100% died 6 days following the removal of DSS (Fig. 3E). Although littermate controls developed significant disease and 25% mortality within 10–12 days, most of the animals successfully return to their original weights by day 15 (Fig. 3D–F). No significant differences in mortality or disease activity were observed between strains administered 1.5% DSS (data not shown).
Representative images of distal colon demonstrate similar progression of DSS-induced epithelial cell necrosis and submucosal edema in both strains from day 0 to day 9 (Fig. 4). Although WT controls had resolved most of the granulocytic inflammation and edema by day 14, CD68TGF-βDNRII mice maintained granulocyte infiltrates and submucosal edema within the colon (Fig. 4A). This contributed to a significantly increased histopathological score (Fig. 4B) and decreased colon length (Fig. 4C) when compared with controls at day 9 and day 14. Recovery of goblet cell numbers within the colon was also markedly delayed in CD68TGF-βDNRII mice compared with WT littermates (Fig. 4D).
CD68 TGF-βDNRII mice show dysregulated cytokine production during colitis resolution
TGF-β is a master regulator of both immunosuppressive and inflammatory cytokine production from a variety of cell types 35, 36. To determine whether the delay in colitis resolution observed in CD68TGF-βDNRII mice was associated with broad defects in cytokine/chemokine production, we evaluated relative production within the colon of both strains at day 14 via protein array. Data expressed as the total pixel intensity (Supporting Information Fig. 2) or fold-difference in pixel intensity within the colonic tissue of CD68TGF-βDNRII mice compared with WT mice (Fig. 5A) revealed multiple abnormalities. Although granulocyte colony stimulating factor (G-CSF), I-309 (CCL1), IL-1-α, IP-10 (CXCL10), and MIP-2 (CXCL2) were highly elevated in CD68TGF-βDNRII mice, the production of IL-10 and MIG (CXCL9) was markedly reduced (Fig. 5A). This defect in IL-10 production from CD68TGF-βDNRII mice was observed in both the colon (Fig. 5B) and the sera (Fig. 5C) as compared with WT controls. CD68TGF-βDNRII mice also produced significantly less TGF-β in the serum and colon tissue during the resolution phase compared with WT (Supporting Information Fig. 3).
CD68TGF-βDNRII mice had only a moderate increase of IFN-γ and no differences in IL-17A when compared with WT (Fig. 5A). Therefore, we asked whether the lack of IL-10 and TGF-β correlated with an increase of type 2 responses. CD68TGF-βDNRII mice produced significantly greater levels of IgE than WT controls at day 14 although there were no differences between strains in IgE levels prior to colitis induction (Fig. 6A). Elevated IgE levels in CD68TGF-βDNRII mice were associated with the increased production of IL-33 within colon tissue (Fig. 6B). Furthermore, greater levels of IL-33 were detected within CD11b+ and CD11b+CD11c+ cells isolated from the lamina propria of CD68TGF-βDNRII mice compared with WT controls at day 14. Taken together, this suggests that TGF-β responsiveness in Mϕs serves an important role in limiting granulocyte recruitment and type 2 inflammation during the resolution of DSS-induced colitis.
Whether TGF-β serves a nonredundant role in Mϕ immunoregulation within the mucosa has been unclear. Herein, we use the DSS-induced model of colitis to demonstrate that CD68TGF-βDNRII mice, which specifically lack TGF-β responsiveness in Mϕs, develop exacerbated gut immunopathology. Interestingly, the marked differences between WT and CD68TGF-βDNRII mice were primarily associated with the resolution of colitic inflammation. Impairment of TGF-β responsiveness in Mϕs delayed the reduction of granulocytic inflammation, impaired IL-10 release, but increased the production of IL-33, a type 2 cytokine that is produced at high levels in the mucosa of UC patients. Hence, TGF-β promotes the normal resolution of intestinal inflammation at least in part, through limiting the production of type 2 cytokines from colonic Mϕs.
CD68 (macrosialin) encodes a type 1 transmembrane protein in mononuclear phagocyte endosomes and its promoter drives Mϕ-specific transgene expression in mice 27, 37. We demonstrate that the CD68 promoter drives transgene expression in colonic F4/80+ and F4/80+ CD11c+ populations, but is only marginally expressed in CD11c+ (specific for dendritic cells) or Gr-1+ cell populations (specific for neutrophils/granulocytes) (Fig. 2) (data not shown). This is distinct from all other myeloid-specific promoters such as human CD11b, c-fms, and lysozyme that confer dendritic cell- and neutrophil-specific expression 38–40. Neutrophils promote oxidative tissue injury during DSS-induced colitis 41 and TGF-β is known to directly modulate neutrophil function in vivo 42, which makes the lack of transgene expression in granulocytes an important issue in this model system. Our data are consistent with prior evidence that the human CD68 promoter is primarily active in mature tissue-resident Mϕ populations 43, 44.
Prior to colitis induction, CD68 TGF-βDNRII mice do not have signs of overt inflammation or tissue injury. On the contrary, mice that lack STAT-3 responsiveness in Mϕs and neutrophils develop spontaneous colitis by 20 wk of age 45. As STAT-3 is an important transcription factor for IL-10 responses 46, this may suggest distinct roles for IL-10 and TGF-β in the regulation of gastrointestinal inflammation. Exacerbated intestinal immunopathology following the cessation of DSS administration in CD68 TGF-βDNRII mice was associated with an extended period of granulocyte infiltration, G-CSF production, chemokine release, and myeloperoxidase (MPO) production (data not shown). This is consistent with prior evidence in this model that excess accumulation of activated Mϕs, neutrophils, eosinophils causes irreparable mucosal damage and lethality 47, 48.
Insufficient IL-10 production may partially explain the increased inflammation in CD68TGF-βDNRII mice, as IL-10-mediated suppression of colitis can be TGF-β dependent 49 and TGF-β induces Mϕs to produce IL-10 34. Furthermore, Mϕs from CD68TGF-βDNRII mice produced significantly less IL-10 following TGF-β stimulation in vitro (Fig. 1E) and in vivo (Fig. 5B and C). This link between TGF-β responsiveness in Mϕs and IL-10 production is consistent with evidence that TGF-β suppresses intestinal inflammation via regulatory Mϕs that produce IL-10 50.
The intestinal injury caused by DSS in rodents shares some characteristics with UC in human patients, as both are characterized by diffuse mucosal inflammation, superficial ulceration, and goblet cell depletion. UC manifests as a TH2 cytokine (IL-4, IL-5, and IL-13)-driven erosion of the intestinal epithelium 23, 24, 51–53. On the contrary, Crohn's colitis is driven by TH1 and TH17 cytokines (IFN-γ, IL-17A/F) 3, 54. Although the etiology of UC remains unclear, recent studies have focused on the role of IL-33, an IL-1 family cytokine that instructs type 2 inflammation 25.
In human UC patients, IL-33 expression is highly upregulated within the intestinal mucosa and IL-33-deficient mice are protected from DSS-induced intestinal immunopathology 23, 24, 55. Our data show that CD68TGF-βDNRII mice produce high levels of IgE and IL-33 within the colon following DSS-induced gut injury. One source of IL-33 in CD68TGF-βDNRII mice was intestinal Mϕs, which demonstrates that TGF-β serves an important role in limiting intestinal inflammation through suppression of IL-33. This may be an important mechanism that could partially explain the reason how mutations in TGF-βRII in humans are associated with increased risk for UC and UC-associated cancer 19, 20. Thus, it is tempting to speculate that blockade of IL-33 during UC may help to reduce the severity of colitis in these patients.
Overall, we demonstrate that mice engineered to have a specific impairment of TGF-β responsiveness in Mϕs develop increased severity of DSS-induced colitis during the resolution phase. This suggests that TGF-β-mediated regulation of Mϕs function serves an important role in the suppression of intestinal inflammation following acute injury. In this regard, it will be important to determine whether CD68TGF-βDNRII mice develop altered susceptibility or resistance to infectious diseases or show defects in tissue repair mechanisms in other model systems.
Materials and methods
The TGF-βDNRII construct was obtained from Dr. Chung Lee at Northwestern University in a plasmid that encodes the extracellular and transmembrane domains, but lacks the cytoplasmic region for human TGF-β receptor II (−5 to 553), which blocks TGF-β responsiveness in vivo 56. This region was subcloned into a modified pcDNA3.1™ (Invitrogen) using Not 1 and Xho 1. The 1 kb promoter sequence from human CD68 (macrosialin) including the 89 bp intronic enhancer (provided by Peter Murray at St. Jude Hospital) 26 was inserted 5′ to TGF-βDNRII as a BamH1-EcoRV fragment and confirmed by restriction digest and DNA sequencing. CD68TGF-βDNRII mice were generated by pronuclear injection of fertilized C57BL/6 oocytes at the University of Cincinnati Transgenic core facility. Offspring were analyzed for genotype by PCR using primers specific for CD68IVS1 and human TGF-β type II. All mice used in the study were age-matched male mice on a C57BL/6 background. All experiments were performed with age-/sex-matched nontransgenic littermates used as controls. All procedures were approved by the institutional IACUC and performed in accordance with all governmental and institutional guidelines.
Genomic DNA from tail biopsies was digested with EcoR1 overnight and 10 μg of digested DNA was resolved in 1% agarose by electrophoresis. Serial dilutions of plasmid containing the CD68TGF-βDNRII were included as a positive control. Gels were denatured, neutralized, and cross-linked using standard protocols. 32P-labeled probe was used for hybridization (49°C) and visualization via autoradiography.
DSS colitis model
DSS (41 kDa) (ICN Biomedical) was used to supplement the drinking water of study animals for 6 days as 1.5, 2, or 2.5% (w/v) solution. Fresh solution was replaced at day 3. After day 6, mice were returned to normal water and monitored for an additional 8 days. Body weight, appearance, occult blood in feces Hem occult test (Beckman Coulter), stool consistency, and diarrhea were recorded daily from coded animals. At time of sacrifice, mice were evaluated for colon length. Disease activity index (DAI) was derived through the evaluation of appearance/activity, diarrhea, and rectal bleeding. DAI=(appearance/activity)+(diarrhea score)+(rectal bleeding score). DAI has a maximum score of 5 determined as follows: Appearance/activity score (0, normal grooming and active versus 1, lack of grooming and lacking normal activity), diarrhea score (0, solid formed stool; 1, loose formed stool; and 2, watery fecal matter), rectal bleeding score (0, no blood; 1, positive hem occult test; 2, gross bleeding from rectum).
Colon histology and histopathology score
Approximately, 1 length of distal colon was removed, fixed in 10% buffered formalin overnight, and kept in 70% ETOH until processing. Tissue was embedded in paraffin and for each colon sample 5 μm sections were cut and stained with H&E or Periodic acid-Schiff (PAS) and examined by light microscopy. Colonic inflammation was evaluated in a blind manner by two observers that estimated the following: (i) percentage of involved area, (ii) amount of follicles, (iii) edema, (iv) erosion/ulceration, (v) crypt loss, (vi) infiltration of polymorphonuclear cells, and (vii) infiltration of mononuclear cells. The percentage of area involved, erosion/ulceration, and the crypt loss was scored on a scale ranging from 0 to 4 as follows: 0, normal; 1, <10%; 2, 10–25%; 3, 25–50%; and 4, >50%. Follicle aggregates were counted and scored as follows: 0, zero to one follicle; 1, two to three follicles; 2, four to five follicles; and 3, six follicles or more. The severity of the other parameters was scored on a scale from 0 to 3 as follows: 0, absent; 1, weak; 2, moderate; and 3, severe. All scores on the individual parameters together could result in a total score ranging from 0 to 24 47.
Peritoneal Mϕs were harvested on day 4 following administration of 4% thioglycollate (Fisher scientific). Lamina propria mononuclear cells were isolated as follows: (i) the entire colon was surgically removed, opened longitudinally, denuded of the epithelial layer by incubation with 0.1% EDTA for 15 min with vigorous shaking at 37°C. (ii) Tissues were washed several times with 1× PBS, minced, and digested with Liberase (Roche) in RPMI for 30 min on an orbital shaker. (iii) Tissue was passed repeatedly through a 16 g syringe, pelleted via centrifugation, resuspended in RPMI, and placed on 30–70% Percoll gradient. (iv) Cells were centrifuged at 2000 rpm for 30 min and mononuclear cells isolated from the interface. Cells were harvested, washed with 1× PBS, and subjected to FACS-staining protocols. FACS buffer (HBSS, 1% FBS, and 0.2% sodium azide) supplemented with anti-FcγRII/RIII mAb (2.4G2) and goat γ globulin (0.5 mg/mL) (Jackson Immunoresearch) was used to prevent nonspecific binding. In some experiments, the isolated mononuclear cells were incubated with a polyclonal PE-labeled mouse anti-human TGF-βRII or anti-mouse TGF-βRII (R&D systems), anti-CD11c (clone N418), anti-CD11b (clone M1/70), or anti-F4/80 (clone BM8) (eBioscience). Anti-mouse IL-33 (clone 396118) from R&D Systems was used for intracellular staining following the addition of Golgi-stop (BD Pharmingen) for 2 h to inhibit protein transport. In some experiments, 7AAD was used to exclude dead cells from analyses. Acquisition was performed with a BD FACSCalibur and analysis was performed with Flojo 7.5.5 or Cellquest software.
Colon tissue lysates were diluted in 1× PBS and subjected to the Proteome Profiler Array™ obtained from R&D Systems according to the manufacturer's instructions. Densitometric evaluation of blots was performed with a Bio-Rad Molecular Imager® Gel Doc™ system. ELISA was used to quantify murine IL-10, TGF-β, and IL-33 (eBioscience).
Statistical significance was assessed by either one-tailed Student's t-test (two groups) or analysis of variance (ANOVA) for multiple groups with a post-hoc Tukey test to determine the significance performed using Prism Graph Pad™.
The authors thank Amanda Roloson and Melissa Mingler for expert technical assistance and Marat Khodoun and Senad Divanovic for critical comments. Funding was provided by NIH grant R01GM083204 and the Department of Veterans Affairs. The British Heart Foundation supports D. R. G.
Conflict of interest: The authors declare no financial or commercial conflict of interest.